<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002482</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000077247</org_study_id>
    <secondary_id>SVMC-ONC-121</secondary_id>
    <secondary_id>NCI-V90-0206</secondary_id>
    <nct_id>NCT00002482</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer</brief_title>
  <official_title>A PHASE I-II TRIAL OF MUROMONAB (OKT-3) WITH LOW-DOSE CYCLOPHOSPHAMIDE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Vincent Medical Center - Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver
      tumor-killing substances to them without harming normal cells.

      PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody and
      cyclophosphamide in treating patients with metastatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the clinical feasibility and toxicity of monoclonal antibody OKT3
      given with low-dose cyclophosphamide in patients with advanced malignancies. II. Perform
      serial immune monitoring on patients treated with this regimen. III. Identify any clinical
      responses produced by this regimen.

      OUTLINE: Biological Response Modifier Therapy with Suppressor Cell Inhibition. Anti-CD3
      Murine Monoclonal Antibody OKT3, MOAB OKT3; with Cyclophosphamide, CTX, NSC-26271.

      PROJECTED ACCRUAL: At least 9 evaluable patients per diagnostic category will be required
      initially; if any response is seen during the dose-finding portion of the study, a total of
      24 patients with that diagnosis will be entered.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 1991</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>antibody therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>biological therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>muromonab-CD3</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Metastatic cancer considered incurable by standard therapy and for
        which no higher priority protocol is available Locally progressive primary brain tumors
        (e.g., astrocytoma, glioma) are also eligible Brain metastases allowed

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-4 (poor performance
        status brain tumor patients specifically eligible) Life expectancy: At least 2 months
        Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Pulmonary: No
        history of adult asthma No emphysema No pulmonary insufficiency No pulmonary edema Other:
        No AIDS or positive HIV serology No pregnant women

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
        Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles L. Wiseman, MD, FACP</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent Medical Center - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>June 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2004</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Muromonab-CD3</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

